Arcus Biosciences
About Us
About Arcus
Leadership
Board of Directors
Scientific Advisory Board
Contact Us
Our Science
SEE PIPELINE
Discovery Candidates
Clinical Candidates
Overview
Anti-TIGIT
Overview
domvanalimab
AB308
Adenosine Pathway
Overview
etrumadenant
quemliclustat
Anti-PD1
zimberelimab
HIF-2⍺
AB521
Clinical Trials
Overview
Investigator Sponsored
Expanded Access Program
Publications
Editorials
Careers
Investors & Media
Press Releases
Events & Presentations
Events Calendar
Presentations
Stock Information
Analyst Coverage
Stock Information
SEC Filings
Corporate Governance
Governance Documents
Management Team
Board of Directors
Committee Composition
Contact Investor Relations
Contact Investor Relations
FAQs
Email Alerts
About Us
About Arcus
Leadership
Board of Directors
Scientific Advisory Board
Contact Us
Our Science
SEE PIPELINE
Discovery Candidates
Clinical Candidates
Overview
Anti-TIGIT
Overview
domvanalimab
AB308
Adenosine Pathway
Overview
etrumadenant
quemliclustat
Anti-PD1
zimberelimab
HIF-2⍺
AB521
Clinical Trials
Overview
Investigator Sponsored
Expanded Access Program
Publications
Editorials
Careers
Investors & Media
Press Releases
Events & Presentations
Events Calendar
Presentations
Stock Information
Analyst Coverage
Stock Information
SEC Filings
Corporate Governance
Governance Documents
Management Team
Board of Directors
Committee Composition
Contact Investor Relations
Contact Investor Relations
FAQs
Email Alerts
Sitemap
ABOUT US
ABOUT ARCUS
LEADERSHIP
BOARD OF DIRECTORS
SCIENTIFIC ADVISORY BOARD
CONTACT US
OUR SCIENCE
SEE PIPELINE
DISCOVERY CANDIDATES
CLINICAL CANDIDATES
Anti-TIGIT
domvanalimab
AB308
Adenosine Pathway
etrumadenant
quemliclustat
Anti-PD1
zimberelimab
HIF-2⍺
AB521
Clinical Trials
Investigator Sponsored
Expanded Access Program
Publications
EDITORIAL
CAREERS
INVESTORS
PRESS RELEASES
EVENTS & PRESENTATIONS
EVENTS CALENDAR
CORPORATE PRESENTATION
STOCK INFORMATION
ANALYST COVERAGE
STOCK INFORMATION
SEC FILINGS
CORPORATE GOVERNANCE
GOVERNANCE DOCUMENTS
MANAGEMENT TEAM
BOARD OF DIRECTORS
COMMITTEE COMPOSITION
CONTACT INVESTOR RELATIONS
CONTACT INVESTOR RELATIONS
FAQS
EMAIL ALERTS